Kalaris Therapeutics, Inc. Market Cap ($48.77 Million)
Market Cap & Net Worth: Kalaris Therapeutics, Inc. (KLRS)
Kalaris Therapeutics, Inc. market cap. Kalaris Therapeutics, Inc. (NASDAQ:KLRS) has a market capitalization of $48.77 Million ($48.77 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #21808 globally and #4877 in its home market, demonstrating a 13.89% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kalaris Therapeutics, Inc.'s stock price $2.05 by its total outstanding shares 23792278 (23.79 Million). Also see how efficiently does Kalaris Therapeutics, Inc. generate cash for how efficiently the company converts equity into cash flow.
Kalaris Therapeutics, Inc. Market Cap History (2025–2026)
Kalaris Therapeutics, Inc. market cap history from 2025 to 2026. Data shows change from $200.81 Million to $48.77 Million (-65.22% CAGR). Check today's stock price for Kalaris Therapeutics, Inc. for real-time trading data and today's change.
Index Memberships
Kalaris Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #620 of 976 |
Weight: Kalaris Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kalaris Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kalaris Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Kalaris Therapeutics, Inc. (KLRS) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of KLRS by Market Capitalization
Companies near Kalaris Therapeutics, Inc. in the global market cap rankings as of November 4, 2026. Also see KLRS total assets for a full breakdown of the balance sheet.
Key companies related to Kalaris Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Kalaris Therapeutics, Inc. (2025–2026)
Market capitalization of Kalaris Therapeutics, Inc. from 2025 to today. Between 2025 and today, Kalaris Therapeutics, Inc.'s market cap moved from $200.81 Million to $ 48.77 Million, with a yearly change of -65.22%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $48.77 Million | -75.71% |
| 2025 | $200.81 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Kalaris Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.77 Million USD |
| MoneyControl | $48.77 Million USD |
| MarketWatch | $48.77 Million USD |
| marketcap.company | $48.77 Million USD |
| Reuters | $48.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more